January 12, 2017
Celyad: First pancreatic cancer patient in its CAR-T NKR-2THINK trial in Belgium
Celyad has activated a second clinical site in Belgium for the , with the registration of a pancreatic cancer patient…
Pharmaceuticals, Biotechnology and Life Sciences
Celyad has activated a second clinical site in Belgium for the , with the registration of a pancreatic cancer patient…
U.S. Patent and Trade Office (USPTO) has decided to uphold Celyad’s U.S. Patent No. 9,181,527, relating to allogeneic human primary…
The first data analysis of the NKR-2 Phase I trial, run by the Belgia’s biopharmaceutical company Celyad, shows encouraging results